We further found that miR-365a-3p inhibits JAK/STAT3 signaling and CRC cell metastatic progression via inhibiting ADAM10 expression, suggesting this pathway may be a viable therapeutic target in those with CRC. The gene discussed is ADAM10; the disease is colorectal carcinoma.